PANEL 3 • 1:30-2:30 pm
Dr. Barnett is the Founder and CEO of Resolute Science, a preclinical-stage biotechnology company developing a novel class of pan-cancer therapeutics targeting aggressive and hard-to-treat solid tumors. Dr. Barnett is a neurosurgeon and director of the neuro-oncology program at Scripps Cancer Center and director of quality assurance for surgical programs.
Resolute Science, Inc. is a San Diego-based preclinical-stage biotech company advancing a pipeline of first-in-class, tumor-agnostic, targeted cytotoxic, and radiopharmaceutical therapeutics for solid tumors. Their MAC-TAC drug delivery platform enables the rapid development of synthetic drug conjugates designed to deliver a broad range of payloads deep into solid tumors. Because they are not restricted to tumor-specific receptors, they can address multiple tumor types with a single drug while overcoming the resistance mechanisms associated with cancer-cell targeting therapeutics.
Casey McPherson is an accomplished singer-songwriter and entrepreneur based in Austin, Texas. Known for his two #10 US hits, he shifted his focus to rare disease advocacy after his daughter Rose was diagnosed with a rare genetic condition. In 2023, he launched Alpha Rose Therapeutics, a platform for the commercialization of rare disease therapeutics.
AlphaRose Therapeutics was founded by Casey McPherson and ex-Genzyme executives. They are focused on developing and commercializing small population genetic treatments at unprecedented scale. Their mission is to revolutionize the delivery of personalized genetic therapies, and expand global access, starting with children who need them the most. Their founding team of scientists, biotech executives, and parents are united by a shared purpose: to create life-changing medicines for children suffering from rare genetic diseases.” Their current lead product, “Rosiphersen,” is slated for clinical trials in late 2025.
Gavenraj Sodhi is a seasoned entrepreneur and technologist specializing in cybersecurity, AI, and robotics. He founded Maddie BioGenetics, driven by a desire to improve healthcare outcomes, particularly for those facing rare diseases and cancer.
Maddie BioGenetics is a biotech startup using AI and LLMs to revolutionize personalized medicine for rare diseases and cancer. Their AI-powered platform, including our copilot Ask Maddie, empowers patients to understand their genetic predispositions and engage in informed discussions with their physicians. They leverage computational simulations to accelerate the development of affordable and effective therapies, making personalized treatment accessible to all.
Herb Sarnoff is a serial entrepreneur with more than 25 years’ experience leading teams and start-up companies in tech and drug discovery. Mr. Sarnoff is also the father of a young woman living with Neurofibromatosis (NF1), a genetic disorder impacting 1 in 3000 births worldwide. Mr. Sarnoff received a BS in engineering from UCSD, an MBA from UCLA, holds over 10 US patents, and made the transition into drug discovery in 2018 to focus on developing treatments for NF1.
Infixion Bioscience was founded to develop drug treatments targeting the underlying root cause of Neurofibromatosis (NF1), a rare genetic disorder that results in ‘benign’ tumors, cognitive and social deficits, scoliosis, chronic pain/itch and high rates of cancer, cardiovascular disease and depression. Infixion is working to raise a $2M Seed round to build on recent positive in vitro results with ASOs (antisense oligonucleotides) and develop proof-of-principle in an NF1 rodent model.
